| March, 2005 | SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo |
| July, 2005 | Head office relocates to Shimbashi, Minato-ku, Tokyo |
| December, 2005 | License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan |
| March, 2006 | Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government |
| March, 2007 | License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore |
| August, 2008 | License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan |
| March, 2009 | SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK) |
| May, 2009 | License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore |
| October, 2010 | SymBio Pharmaceuticals announces NDA Approval of TREAKISYM® (bendamustine) in Japan |
| December, 2010 | SymBio Pharmaceuticals launches TREAKISYM® in Japan |
| July, 2011 | Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 (rigosertib, a Phase Ⅲ stage multi-kinase inhibitor for Myelodysplastic Syndromes) |
| October, 2011 | Listed on Osaka Securities Exchange JASDAQ Growth Market |
| November, 2014 | Head Office relocates to Toranomon, Minato-ku, Tokyo |
| May, 2016 | SymBio Pharma USA, Inc. established at Menlo Park, California, USA |
| August, 2016 | SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of chronic lymphocytic leukemia in Japan |
| December, 2016 | SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan |
| September, 2017 |
Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan
*RTD: Ready-to-dilute, RI: Rapid Infusion |
| July, 2018 | TREAKISYM® (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018 |
| September, 2019 | SymBio Pharmaceuticals obtained from Chimerix (NASDAQ:CMRX) the exclusive worldwide rights to develop, manufacture, and commercialize the antiviral drug brincidofovir (BCV) excluding the prevention and treatment of smallpox |
| September, 2020 | SymBio Pharmaceuticals receives approval of TREAKISYM® Ready-To-Dilute (RTD) formulation |
| December, 2020 | Commencement of in-house sales of the anti-cancer agent TREAKISYM® |
| January, 2021 | Market Launch of TREAKISYM® Ready-To-Dilute (RTD) Formulation |
| March, 2021 | SymBio Pharmaceuticals receives approval of TREAKISYM® (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma |
| April, 2021 | SymBio Pharmaceuticals receives approval of TREAKISYM® Ready-To-Dilute (RTD) Formulation in combination with rituximab ,and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma |
| February, 2022 | SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM® Liquid Formulation |
Privacy Policy | Privacy Notice for Clinical Trials in UK | Terms of Use
Copyright © SymBio Pharmaceuticals Limited. All rights reserved.
